Table.
Cases of Ocular-type Anti-PD-1-associated MG.
| Case/age (y)/sex | Cancer | PD-1 | Onset | Diplopia/ ptosis |
AChR/ MuSK/titin |
CK U/L | Treatment | Outcome | Reference number |
|---|---|---|---|---|---|---|---|---|---|
| 1/65/M | NSCLC | Nivolumab | 25 days | +/+ | -/-/ND | ND | ChEI | CR | 4 |
| 2/81/M | Melanoma | Pembrolizumab | 58 days | +/+ | -/ND/ND | ND | PRED | CR | 5 |
| 3/74/F | Melanoma | Nivolumab | 28 days | +/+ | 4.0/ND/ND | 654 | ChEI, PRED | PR | 3 |
| 4/57/M | NSCLC | Nivolumab | 58 days | +/- | 0.5/ND/ND | 57 | ChEI, PRED | MM | 3 |
| 5/73/M | NSCLC | Pembrolizumab | 23 days | +/+ | -/-/+ | 7,311 | PRED | CR | Present |
NSCLC: non-small-cell lung cancer, ChEI: cholinesterase inhibitor, PRED: prednisolone, CR: complete response, MM: minimal manifestation, PR: partial response, N/D: no data, Onset: the time between the appearance of MG symptoms and the administration of anti-PD-1 monoclonal antibody